Sudubrilimab (HS636), an Ig G1-kappa monoclonal antibody targeting PDL1, is engineered with a TGF-beta1 receptor II ectodomain (TGFBR2-ECD) fused to its C-terminus. This design enables Sudubrilimab to simultaneously inhibit the PD-1/PD-L1 pathway and TGF-beta
* VAT and and shipping costs not included. Errors and price changes excepted